Showing results (61-70 of 75) with videos related to
Sort By:
Pageof 8
Frontiers in Public Health|December 19, 2022
The design and implementation of natural population cohort study Biobank: A multiple-center project cooperation with medical consortia in Southwest ChinaPing Fan, Shu Zhang, Weiya Wang, et al.Future Oncology (London, England)|July 18, 2019
Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancerJesús Corral, Tony S Mok, Kazuhiko Nakagawa, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancersPatricia M LoRusso, Smitha S Krishnamurthi, John J Rinehart, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 5, 2016
Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse modelMingyao Meng, Wenju Wang, Jun Yan, et al.Oncotarget|October 27, 2015
ZNF32 protects against oxidative stress-induced apoptosis by modulating C1QBP transcriptionKai Li, Bo Gao, Jun Li, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 5, 2016
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung CancerSai-Hong Ignatius Ou, Ramaswamy Govindan, Keith D Eaton, et al.Future Oncology (London, England)|November 29, 2019
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancerJeffrey W Clark, D Ross Camidge, Eunice L Kwak, et al.Cancer Medicine|March 11, 2015
Complex renal cysts associated with crizotinib treatmentPatrick Schnell, Cynthia H Bartlett, Benjamin J Solomon, et al.Nature Communications|June 18, 2021
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancerKamrine E Poels, Adam J Schoenfeld, Alex Makhnin, et al.The Journal of Biological Chemistry|October 19, 2018
A dynamic transcriptomic atlas of cytokine-induced killer cellsMingyao Meng, Lin Li, Ruhong Li, et al.Pageof 8